Drug Profile
Research programme: PCSK9 protein inhibitors - HitGen
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator HitGen
- Class Antihyperlipidaemics; Macrocyclic compounds
- Mechanism of Action PCSK9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Acute coronary syndromes; Atherosclerosis
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Acute coronary syndromes in China (PO)
- 28 Apr 2021 No recent reports of development identified for research development in Atherosclerosis in China (PO)
- 02 Mar 2017 PCSK9 protein inhibitors - HitGen is available for licensing as of 02 Mar 2017. http://www.hitgen.com/?page_id=7105 (HitGen pipeline, March 2017)